Article Versions Notes

Dolat M, Macaire P, Goirand F, Vincent J, Hennequin A, Palmier R, Bengrine-Lefevre L, Ghiringhelli F, Royer B, Schmitt A. Association of 5-FU Therapeutic Drug Monitoring to DPD Phenotype Assessment May Reduce 5-FU Under-Exposure. Pharmaceuticals. 2020; 13(11):416. https://doi.org/10.3390/ph13110416

Dolat, Marine, Pauline Macaire, Françoise Goirand, Julie Vincent, Audrey Hennequin, Rémi Palmier, Leïla Bengrine-Lefevre, François Ghiringhelli, Bernard Royer, and Antonin Schmitt. 2020. "Association of 5-FU Therapeutic Drug Monitoring to DPD Phenotype Assessment May Reduce 5-FU Under-Exposure" Pharmaceuticals 13, no. 11: 416. https://doi.org/10.3390/ph13110416

Dolat, M., Macaire, P., Goirand, F., Vincent, J., Hennequin, A., Palmier, R., Bengrine-Lefevre, L., Ghiringhelli, F., Royer, B., & Schmitt, A. (2020). Association of 5-FU Therapeutic Drug Monitoring to DPD Phenotype Assessment May Reduce 5-FU Under-Exposure. Pharmaceuticals, 13(11), 416. https://doi.org/10.3390/ph13110416